Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 9/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31172568 | 0.97 | ALB (0.55) | ALBFTOMEN1MAPTHPGD | |
| SCHEMBL917141 | 0.93 | ALB (0.58) | ALBFTOMEN1MAPTHPGD | |
| SCHEMBL28607477 | 0.90 | FTO (0.53) | ALBFTOMEN1MAPTHPGD | |
| SCHEMBL7877596 | 0.90 | FTO (0.52) | ALBFTOMEN1MAPTHPGD | |
| SCHEMBL26030595 | 0.90 | FTO (0.52) | ALBFTOMEN1MAPTHPGD | |
| SCHEMBL25362908 | 0.89 | FTO (0.51) | ALBFTOMEN1MAPTHPGD | |
| SCHEMBL19835756 | 0.89 | FTO (0.53) | ALBFTOMEN1MAPTHPGD | |
| Isothiocyanate SCHEMBL27141128 | 0.88 | ALB (0.54) | ALBFTOMEN1MAPTHPGD | |
| SCHEMBL21549529 | 0.88 | FTO (0.50) | ALBFTOMEN1MAPTHPGD | |
| SCHEMBL22100544 | 0.87 | FTO (0.54) | ALBFTOMEN1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250464-B1 | DETECTION OF HUMAN HEPATITIS B VIRUS SURFACE ANTIGEN MUTANTS BY SPECIFIC AMPLIFICATION AND ITS APPLICATION ON GENE CHIP | GOVERNMENT OF THE REPUBLIC OF (SG) | 2007-02-21 | — | — | EP | claimed |
| US-6759193-B2 | SYNTHETIC OLIGONUCLEOTIDES FOR USE IN IMMUNOTHERAPY | THE GOVERNMENT OF THE REPUBLIC OF SINGAPORE (SG) | 2004-07-06 | — | — | US | claimed |
| US-20030003549-A1 | DETECTION OF HUMAN HEPATITIS B VIRUS SURFACE ANTIGEN MUTANTS BY SPECIFIC AMPLIFICATION AND ITS APPLICATION ON GENE CHIP | GOVERNMENT OF THE REPUBLIC OF SINGAPORE, THE (SG) | 2003-01-02 | — | — | US | claimed |
| US-11124522-B2 | Chemosensor and a method of detecting palladium ions | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2021-09-21 | — | — | US | disclosed |
| US-20200392148-A1 | CHEMOSENSOR AND A METHOD OF DETECTING PALLADIUM IONS | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2020-12-17 | — | — | US | disclosed |
| US-20160024138-A1 | METHOD FOR DEBLOCKING OF LABELED OLIGONUCLEOTIDES | LIFE TECHNOLOGIES CORP (US) | 2016-01-28 | — | — | US | disclosed |
| US-9085797-B2 | Method for deblocking of labeled oligonucleotides | Life Technologies Corporation (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140066612-A1 | METHOD FOR DEBLOCKING OF LABELED OLIGONUCLEOTIDES | Life Technologies Corporation (US) | 2014-03-06 | — | — | US | disclosed |
| US-8524882-B2 | Method for deblocking of labeled oligonucleotides | Life Technologies Corporation (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120253028-A1 | METHOD FOR DEBLOCKING OF LABELED OLIGONUCLEOTIDES | Life Technologies Corporation (US) | 2012-10-04 | — | — | US | disclosed |
| US-8093372-B2 | Contacting with nucleophilic compound | Life Technologies Corporation (US) | 2012-01-10 | — | — | US | disclosed |
| US-20030120063-A1 | Method for deblocking of labeled oligonucleotides | INVITROGEN CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20030003549-A1 | DETECTION OF HUMAN HEPATITIS B VIRUS SURFACE ANTIGEN MUTANTS BY SPECIFIC AMPLIFICATION AND ITS APPLICATION ON GENE CHIP | GOVERNMENT OF THE REPUBLIC OF SINGAPORE, THE (SG) | 2003-01-02 | — | — | US | disclosed |
| EP-1228076-A4 | A SUBSTANTIALLY CELL MEMBRANE IMPERMEABLE COMPOUND AND USE THEREOF | UNISEARCH LTD (AU) | 2002-11-06 | — | — | EP | disclosed |
| EP-1250464-A2 | DETECTION OF HUMAN HEPATITIS B VIRUS SURFACE ANTIGEN MUTANTS BY SPECIFIC AMPLIFICATION AND ITS APPLICATION ON GENE CHIP | The Government of the Republic of Singapore, Attorney General's Chambers (SG) | 2002-10-23 | — | — | EP | disclosed |
| WO-2002074305-A1 | USE OF A SUBSTANTIALLY CELL MEMBRANE IMPERMEABLE COMPOUND FOR TREATING ARTHRITIS | UNISEARCH LIMITED (AU) | 2002-09-26 | — | — | WO | disclosed |
| EP-1228076-A1 | A SUBSTANTIALLY CELL MEMBRANE IMPERMEABLE COMPOUND AND USE THEREOF | UNISEARCH LIMITED (AU) | 2002-08-07 | — | — | EP | disclosed |
| WO-2000071559-A9 | METHOD FOR DEBLOCKING OF LABELED OLIGONUCLEOTIDES | INVITROGEN CORP (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001021628-A1 | A SUBSTANTIALLY CELL MEMBRANE IMPERMEABLE COMPOUND AND USE THEREOF | UNISEARCH LIMITED (AU) | 2001-03-29 | — | — | WO | disclosed |
| WO-2001007652-A2 | DETECTION OF HUMAN HEPATITIS B VIRUS SURFACE ANTIGEN MUTANTS BY SPECIFIC AMPLIFICATION AND ITS APPLICATION ON GENE CHIP | THE GOVERNMENT OF THE REPUBLIC OF SINGAPORE (SG) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120063-A1 | Method for deblocking of labeled oligonucleotides | DCLRE1B, DDB1, DTYMK | ALB 2669/4885FTO 1256/4885MEN1 3091/4885 |
| US-11124522-B2 | Chemosensor and a method of detecting palladium ions | DDT, PDCD1, PDCD10 | ALB 108/4885FTO 766/4885MEN1 3564/4885 |
| US-20120253028-A1 | METHOD FOR DEBLOCKING OF LABELED OLIGONUCLEOTIDES | DCLRE1B, DDB1, DTYMK | ALB 2669/4885FTO 1256/4885MEN1 3091/4885 |
| US-20200392148-A1 | CHEMOSENSOR AND A METHOD OF DETECTING PALLADIUM IONS | DDT, PDCD1, PDCD10 | ALB 108/4885FTO 766/4885MEN1 3564/4885 |
| US-20160024138-A1 | METHOD FOR DEBLOCKING OF LABELED OLIGONUCLEOTIDES | DCLRE1B, DDB1, DTYMK | ALB 2669/4885FTO 1256/4885MEN1 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.